No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) May Have Issues Allocating Its Capital
Baiyunshan Pharmaceutical's Unit Gets Nod to Cefuroxime Sodium for Injection's Amendment
BAIYUNSHAN PH (600332.SH): Sodium cefazolin for injection passed the consistency evaluation of generic drugs.
On December 13th, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its controlling subsidiary, Guangzhou BAIYUNSHAN TIANXIN Pharmaceutical Co., Ltd., received the "Notice of Approval for Supplementary Application of Pharmaceutical" issued by the National Medical Products Administration, indicating that injectable Cefazolin Sodium (1.0g, 0.5g) has passed the consistency evaluation of quality and efficacy for generic drugs. Cefazolin Sodium is a third-generation cephalosporin, primarily used to treat lower respiratory tract infections, urinary tract infections, intra-abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae, and mon...
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Baiyunshan (00874.HK) saw a shareholding reduction of 0.348 million shares by Norges Bank.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on November 27, 2024, baiyunshan ph (00874.HK) was sold by Norges Bank on the exchange at an average price of HKD 18.0525 per share, selling 0.348 million shares, involving approximately 6.2823 million Hong Kong dollars. After the shareholding, Norges Bank's latest number of shares held is 10.855 million shares, and the shareholding ratio has decreased from 5.09% to 4.94%.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
